Recommendations for thrombotic risk stratification and targeted thromboprophylaxis in women during assisted reproduction

1. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ, 3rd. Trends in the incidence of venous thromboembolism during preg­nancy or postpartum: a 30-year population-based study. Ann Int Med. 2005; 143 (10): 697–706. doi: 10.7326/0003-4819-143-10-200511150-00 006.

2. Sultan AA, West J, Tata LJ, Fleming KM, Nel­son-Piercy C, Grainge MJ. Risk of first venous thromboembolism in and around pregnancy: a population-based cohort study. Br J Haematol. 2012; 156 (3): 366–373. doi: 10.1111/j.13 65-2141. 2011.08956.x.

3. Bates SM, Middeldorp S, Rodger M, James AH, Greer I. Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. J Thromb Thrombolysis. 2016; 41 (1): 92–128. doi: 10.1007/s11239-015-1309-0.

4. Pomp ER, Lenselink AM, Rosendaal FR, Dog­gen CJ. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost. 2008; 6 (4): 632–637. doi: 10.1111/j.15 38-7836.2008.02921.x.

5. Jackson E, Curtis KM, Gaffield ME. Risk of venous thromboembolism during the post­partum period: a systematic review. Obstet Gynecol. 2011; 117 (3): 691–703. doi: 10.1097/AOG. 0b013e31820ce2db.

6. Kamel H, Navi BB, Sriram N, Hovsepian DA, Devereux RB, Elkind MS. Risk of a thrombotic event after the 6-week postpartum period. N Engl J Med. 2014; 370 (14): 1307–1315. doi: 10.1056/NEJMoa1311485.

7. Middeldorp S, Naue C, Köhler C. Thrombophilia, thrombosis and thromboprophylaxis in pregnancy: for what and in whom? Hamostaseologie. 2022; 42 (1): 54–64. doi: 10.1055/a-1717-7663.

8. James AH, Jamison MG, Brancazio LR, Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol. 2006; 194 (5): 1311–1315. doi: 10.1016/ j.ajog.2005.11.008.

9. Ray JG, Chan WS. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. Obstet Gynecol Surv. 1999; 54 (4): 265–271. doi: 10.1097/00006254-199904000-00023.

10. Jacobsen AF, Skjeldestad FE, Sandset PM. Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium--a register-based case-control study. Am J Obstet Gynecol. 2008; 198 (2): 233.e231–e237. doi: 10.1016/j.ajog.2007.08.041.

11. Samuelsson E, Hedenmalm K, Persson I. Mortality from venous thromboembolism in young Swedish women and its relation to pregnancy and use of oral contraceptives--an approach to specifying rates. Eur J Epidemiol. 2005; 20 (6): 509–516. doi: 10.1007/s10654-005-4266-7.

12. Creanga AA, Berg CJ, Syverson C, Seed K, Bruce FC, Callaghan WM. Pregnancy-related mortality in the United States, 2006-2010. Obstet Gynecol. 2015; 125 (1): 5–12. doi: 10.1097/aog. 0000000000000564.

13. Cantwell R, Clutton-Brock T, Cooper G, et al. Saving Mothers‘ Lives: Reviewing maternal deaths to make motherhood safer: 2006-2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG: Int J Obstetr Gynaecol. 2011; 118 (Suppl 1): 1–203. doi: 10.1111/j.1471-0528.2010.02847.x.

14. Berg CJ, Chang J, Callaghan WM, Whitehead SJ. Pregnancy-related mortality in the United States, 1991-1997. Obstet Gynecol. 2003; 101 (2): 289–296. doi: 10.1016/s0029-7844 (02) 02587-5.

15. Chang J, Elam-Evans LD, Berg CJ, et al. Pregnancy-related mortality surveillance – United States, 1991–1999. MMWR Surveill Summ. 2003; 52 (2): 1–8.

16. Henriksson P, Westerlund E, Wallen H, Brandt L, Hovatta O, Ekbom A. Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilisation: cross sectional study. BMJ. 2013; 346: e8632. doi: 10.1136/bmj. e8632.

17. Rova K, Passmark H, Lindqvist PG. Venous thromboembolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful cycles. Fertil Steril. 2012; 97 (1): 95–100. doi: 10.1016/ j.fertnstert.2011.10.038.

18. Hansen AT, Kesmodel US, Juul S, Hvas AM. Increased venous thrombosis incidence in pregnancies after in vitro fertilization. Hum Reprod. 2014; 29 (3): 611–617. doi: 10.1093/humrep/det458.

19. Filipovic-Pierucci A, Gabet A, Deneux-Tharaux C, Plu-Bureau G, Olié V. Arterial and venous complications after fertility treatment: A French nationwide cohort study. Eur J Obstetr Gynecol Reprod Biol. 2019; 237: 57–63. doi: 10.1016/j.ejogrb.2019.02.034.

20. Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141 (Suppl 2): e691S–e736S. doi: 10.1378/chest.11-2300.

21. Chan WS, Rey E, Kent NE, et al. Venous thromboembolism and antithrombotic therapy in pregnancy. J Obstet Gynaecol Can. 2014; 36 (6): 527–553. doi: 10.1016/s1701-2163 (15) 30569-7.

22. Sennström M, Rova K, Hellgren M, et al. Thromboembolism and in vitro fertilization – a systematic review. Acta Obstet Gynecol Scand. 2017; 96 (9): 1045–1052. doi: 10.1111/aogs.13147.

23. Pabinger I, Grafenhofer H, Kyrle PA, et al. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. Blood. 2002; 100 (3): 1060–1062. doi: 10.1182/blood-2002-01-0149.

24. De Stefano V, Martinelli I, Rossi E, et al. The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. Br J Haematol. 2006; 135 (3): 386–391. doi: 10.1111/j.1365-2141.2006.06317.x.

25. Rodger M. Pregnancy and venous thromboembolism: ‚TIPPS‘ for risk stratification. Hematology Am Soc Hematol Educ Program. 2014; 2014 (1): 387–392. doi: 10.1182/asheducation- 2014.1.387.

26. Arachchillage DJ, Mackillop L, Chandratheva A, Motawani J, MacCallum P, Laffan M. Guidelines for thrombophilia testing: A British Society for Haematology guidelines. Br J Haematol. 2022. e-pub ahead of print 20220529; doi: 10.1111/bjh.18239.

27. Arachchillage DRJ, Makris M. Inherited thrombophilia and pregnancy complications: should we test? Semin Thromb Hemost. 2019; 45 (1): 50–60. doi: 10.1055/s-0038-1657782

28. Gerhardt A, Scharf RE, Greer IA, Zotz RB. Hereditary risk factors for thrombophilia and probability of venous thromboembolism during pregnancy and the puerperium. Blood. 2016; 128 (19): 2343–2349. doi: 10.1182/blood- 2016-03-703728.

29. Middeldorp S. Inherited thrombophilia: a double-edged sword. Hematology Am Soc Hematol Educ Program. 2016; 2016 (1): 1–9. doi: 10.1182/asheducation-2016.1.1.

30. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Int Med. 2007; 146 (12): 857–867.

31. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4 (2): 295–306. doi: 10.1111/j.1538-7836.2006.01753.x.

32. Devreese KMJ, Ortel TL, Pengo V, de Laat B. Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. J Thromb Haemost. 2018; 16 (4): 809–813. doi: 10.1111/jth.13976.

33. Quenby S, Farquharson RG, Dawood F, Hughes AM, Topping J. Recurrent miscarriage and long-term thrombosis risk: a case-control study. Hum Reprod. 2005; 20 (6): 1729–1732. doi: 10.1093/humrep/deh844.

34. James AH. Pregnancy-associated thrombosis. Hematology Am Soc Hematol Educ Program. 2009; 2009: 277–285. doi: 10.1182/ash­- education-2009.1.277.

35. Petri M. Epidemiology of the Antiphospholipid Syndrome. In: Asherson RA CR, Piette J-CH, Shoenfeld Y (ed) The antiphosholipid syndrome. 1st ed. Boca Raton, CRC Press, 1996; 13–28.

36. Bates SM, Rajasekhar A, Middeldorp S, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv. 2018; 2 (22): 3317–3359. doi: 10.1182/bloodadvances.2018024802.

37. Jacobsen AF, Skjeldestad FE, Sandset PM. Ante- and postnatal risk factors of venous thrombosis: a hospital-based case-control study. J Thromb Haemost. 2008; 6 (6): 905–912. doi: 10.1111/j.1538-7836.2008.02961.x.

38. Grandone E, Colaizzo D, Vergura P, et al. Age and homocysteine plasma levels are risk factors for thrombotic complications after ovarian stimulation. Hum Reprod. 2004; 19 (8): 1796–1799. doi: 10.1093/humrep/deh346.

39. Rogolino A, Coccia ME, Fedi S, et al. Hypercoagulability, high tissue factor and low tissue factor pathway inhibitor levels in severe ovarian hyperstimulation syndrome: possible association with clinical outcome. Blood Coagul Fibrinolysis: Int J Haemost Thromb. 2003; 14 (3): 277–282. doi: 10.1097/01.mbc.0000061296.28953.d0.

40. Biron C, Galtier-Dereure F, Rabesandratana H, et al. Hemostasis parameters during ovarian stimulation for in vitro fertilization: results of a prospective study. Fertil Steril. 1997; 67 (1): 104–109. doi: 10.1016/s0015-0282 (97) 81864-x.

41. Curvers J, Nap AW, Thomassen MC, et al. Effect of in vitro fertilization treatment and subsequent pregnancy on the protein C pathway. Br J Haematol. 2001; 115 (2): 400–407. doi: 10.1046/j.1365-2141.2001.03118.x.

42. Nelson SM. Prophylaxis of VTE in women – during assisted reproductive techniques. Thromb Res. 2009; 123 (Suppl 3): S8–S15. doi: 10.1016/s0049-3848 (09) 70127-6.

43. Westerlund E, Henriksson P, Wallén H, Hovatta O, Wallberg KR, Antovic A. Detection of a procoagulable state during controlled ovarian hyperstimulation for in vitro fertilization with global assays of haemostasis. Thromb Res. 2012; 130 (4): 649–653. doi: 10.1016/j.thromres.2011.11.024.

44. Westerlund E, Antovic A, Hovatta O, et al. Changes in von Willebrand factor and ADAMTS13 during IVF. Blood Coagul Fibrinolysis: Int J Haemost Thromb. 2011; 22 (2): 127–131. doi: 10.1097/MBC.0b013e32834363ea.

45. Balandina AN, Koltsova EM, Teterina TA, et al. An enhanced clot growth rate before in vitro fertilization decreases the probability of pregnancy. PLoS One. 2019; 14 (5): e0216724. doi: 10.1371/journal.pone.0216724.

46. Harnett MJ, Bhavani-Shankar K, Datta S, Tsen LC. In vitro fertilization-induced alterations in coagulation and fibrinolysis as measured by thromboelastography. Anesth Analg. 2002; 95 (4): 1063–1066. doi: 10.1097/000 00539-200210000-00050.

47. Yáñez-Mó M, Siljander PR, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicl. 2015; 4: 27066. doi: 10.3402/jev.v4.27066.

48. Nomura S, Shimizu M. Clinical significance of procoagulant microparticles. J Intens Care. 2015; 3 (1): 2. doi: 10.1186/s40560-014-00 66-z.

49. Li C, Su YF, Jin L, et al. Association between higher levels of serum estradiol and elevated levels of fibrin (fibrinogen) degradation products in late pregnancy following assisted reproductive technology treatment. Thromb Res. 2020; 187: 63–71. doi: 10.1016/ j.thromres.2019.12.024.

50. Lattová V, Dostál J, Vodička J, Procházka M. Riziko tromboembolie v souvislosti s in vitro fertilizací. Ceska Gynekol. 2019; 84 (3): 229–232.

51. Olausson N, Mobarrez F, Wallen H, Westerlund E, Hovatta O, Henriksson P. Microparticles reveal cell activation during IVF – a possible early marker of a prothrombotic state during the first trimester. Thromb Haemost. 2016; 116 (3): 517–523. doi: 10.1160/th15-12-0970.

52. Olausson N, Discacciati A, Nyman AI, et al. Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilization with fresh respectively frozen-thawed embryo transfer: Nationwide cohort study. J Thromb Haemost. 2020; 18 (8): 1965–1973. doi: 10.1111/jth.14840.

53. Chan WS, Ginsberg JS. A review of upper extremity deep vein thrombosis in pregnancy: unmasking the ‚ART‘ behind the clot. J Thromb Haemost. 2006; 4 (8): 1673–1677. doi: 10.1111/j.1538-7836.2006.02026.x.

54. Nelson SM, Greer IA. Thrombophilia and the risk for venous thromboembolism during pregnancy, delivery, and puerperium. Obstet Gynecol Clin North Am. 2006; 33 (3): 413–427. doi: 10.1016/j.ogc.2006.05.009.

55. Jacobsen AF, Sandset PM. Prior thromboembolic disease and assisted reproductive therapy. Semin Reprod Med. 2021; 39 (5–06): 180–185. doi: 10.1055/s-0041-1732375.

56. Henriksson P. Cardiovascular problems associated with IVF therapy. J Intern Med. 2021; 289 (1): 2–11. doi: 10.1111/joim.13136.

57. Gurunath S, Vinekar S, Biliangady R. Assisted reproductive techniques in a patient with history of venous thromboembolism: a case report and review of literature. J Hum Reprod Sci. 2018; 11 (2): 193–197. doi: 10.4103/jhrs.JHRS_58_17.

58. Hart C, Bauersachs R, Scholz U, et al. Prevention of venous thromboembolism during pregnancy and the puerperium with a special focus on women with hereditary thrombophilia or prior VTE-position paper of the Working Group in Women‘s Health of the Society of Thrombosis and Haemostasis (GTH). Hamostaseologie. 2020; 40 (5): 572–590. doi: 10.1055/a-1132-0750.

59. Bistervels IM, Scheres LJJ, Hamulyák EN, Middeldorp S. Sex matters: Practice 5P‘s when treating young women with venous thromboembolism. J Thromb Haemost. 2019; 17 (9): 1417–1429. doi: 10.1111/jth.14549.

60. Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women‘s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017; 76 (3): 476–485. doi: 10.1136/annrheumdis-2016-209770.

61. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005; 106 (2): 401–407. doi: 10.1182/blood-2005-02-0626.

62. Gándara E, Carrier M, Rodger MA. Intermediate doses of low-molecular-weight heparin for the long-term treatment of pregnancy thromboembolism. A systematic review. Thromb Haemost. 2014; 111 (3): 559–561. doi: 10.1160/th13-06-0510.

63. Cox S, Eslick R, McLintock C. Effectiveness and safety of thromboprophylaxis with enoxaparin for prevention of pregnancy-associated venous thromboembolism. J Thromb Haemost. 2019; 17 (7): 1160–1170. doi: 10.1111/jth.14452.

64. Romualdi E, Dentali F, Rancan E, et al. Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature. J Thromb Haemost. 2013; 11 (2): 270–281. doi: 10.1111/jth.12085.

65. Lindqvist PG, Bremme K, Hellgren M. Efficacy of obstetric thromboprophylaxis and long-term risk of recurrence of venous thromboembolism. Acta Obstet Gynecol Scand. 2011; 90 (6): 648–653. doi: 10.1111/j.1600-0412.2011.01098.x.

66. ACOG Practice Bulletin No. 196: Thromboembolism in pregnancy. Obstet Gynecol. 2018; 132 (1): e1–e17. doi: 10.1097/aog.00000000 00002706.

67. ACOG Practice Bulletin No. 196: Thromboembolism in pregnancy: correction. Obstet Gynecol. 2018; 132 (4): 1068. doi: 10.1097/aog.0000 000000002923.

68. Pabinger I, Thaler J. How I treat patients with hereditary antithrombin deficiency. Blood. 2019; 134 (26): 2346–2353. doi: 10.1182/blood. 2019002927.

69. Clark P, Greer IA. Prevention and treatment of arterial thrombosis in pregnancy. Semin Thromb Hemost. 2003; 29 (2): 155–164. doi: 10.1055/s-2003-38830.

70. Haapsamo M, Martikainen H, Tinkanen H, Heinonen S, Nuojua-Huttunen S, Räsänen J. Low-dose aspirin therapy and hypertensive pregnancy complications in unselected IVF and ICSI patients: a randomized, placebo-controlled, double-blind study. Hum Reprod. 2010; 25 (12): 2972–2977. doi: 10.1093/humrep/deq286.

71. Wang L, Huang X, Li X, et al. Efficacy evaluation of low-dose aspirin in IVF/ICSI patients evidence from 13 RCTs: A systematic review and meta-analysis. Medicine (Baltimore). 2017; 96 (37): e7720. doi: 10.1097/md.0000000000007720.

72. Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019; 78 (10): 1296–1304. doi: 10.1136/annrheumdis-2019-215213.

73. Mazzolai L, Ageno W, Alatri A, et al. Second consensus document on dia­gnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC Working Group on Aorta and Peripheral Vascular Dis­eases and the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. Eur J Prev Cardiol. 2022; 29 (8): 1248–1263. doi: 10.1093/eurjpc/zwab088.